



T: 49.69.7422.0131  
sebastian.burgis@skadden.com

## Education

Second State Exam, Higher Regional Court Bamberg, 2019

First State Exam, University of Würzburg School of Law, 2016

## Bar Admissions

Frankfurt am Main

Sebastian Burgis primarily focuses on capital markets transactions and corporate matters, advising clients in a variety of industries. His recent significant representations include:

- **MorphoSys AG** in:

- its pending €2.7 billion sale to, and public takeover by, Novartis and the simultaneous disposition of the worldwide marketing rights of its antibody drug Monjuvi to Incyte Corporation
- connection with a cash capital increase with gross proceeds of approximately €102.7 million and the issuance of a US\$300 million development funding bond

- **Armira** in its €30 million anchor investment as part of a €60 million private placement of new shares in tonies SE

- **Silver Lake** in its strategic partnership and investment in German publicly listed company Software AG via the purchase of €344 million aggregate principal amount of subordinated unsecured convertible notes. This is the first PIPE by any U.S. technology investment firm in a German public company

- Berenberg as sole global coordinator and joint bookrunner and Stifel as additional joint bookrunner in connection with a capital increase of **Pacifico Renewables Yield AG**

- Deutsche Bank, Goldman Sachs and J.P. Morgan as joint bookrunners in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of **ABOUT YOU Holding AG**

- **SIGNA Sports United GmbH** in connection with its US\$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Prior to joining Skadden, Mr. Burgis gained experience as a law clerk in the Frankfurt and Brussels offices of other international law firms.